McMaster University Medical Centre

ivWatch Technology Demonstrates High Sensitivity in Wilhelmina Children's Hospital Study

Retrieved on: 
Tuesday, July 11, 2023
IV, NICU, QI, PDSA, Blood, Incidence, Journal, Patient, McMaster University Medical Centre, Quality, Observation, JVA, Hospital, Claude Pivi, BMJ Open, Medical device, Risk management, Medical imaging, NEWS

NEWPORT NEWS, Va., July 11, 2023 /PRNewswire/ -- A new study published in The Journal of Vascular Access (JVA) examines several important metrics that describe the performance of the ivWatch patient monitoring system for infiltrations and extravasations in a 24-bed neonatal intensive care unit (NICU) at Wilhelmina Children's Hospital, part of the University Medical Centre of Utrecht in the Netherlands. The continuous IV monitoring system was deployed to identify the leakage of infused fluids via short peripheral IV catheters (PIVC), which are commonplace with neonatal patients and are placed more than 200 times monthly in this NICU. This condition is referred to as peripheral IV infiltration/extravasation (PIVIE).

Key Points: 
  • During the monitoring time of the study with ivWatch technology, 11 infiltrations were detected in 21 monitored PIVCs, which corresponds to a 52.4% infiltration incidence rate.
  • The study was conducted using the PDSA (plan, do, study, act) model of quality improvement (QI) to provide a systematic framework for identifying PIVIE risks and evaluating the ivWatch model 400's continuous monitoring of PIVCs.
  • The ivWatch system has been clinically tested in laboratory and real-world settings, demonstrating high sensitivity and specificity across various patient populations.
  • The study concluded: "Continuous infusion site monitoring using the ivWatch [system] suggests this technology offers the potential to detect PIVIE events earlier than relying on intermittent observation alone (i.e.

Amolyt Pharma to Host Hybrid Key Opinion Leader Event on Eneboparatide, a PTHR1 Agonist Entering Phase 3 for the Treatment of Hypoparathyroidism, in Chicago on June 16, 2023

Retrieved on: 
Wednesday, June 7, 2023
KOL, PTHR1, FACP, FACE, Hypoparathyroidism, Patient, McMaster University Medical Centre, FRCPC, Disease, Pharmaceutical industry, Calypso

The event will also be webcasted for those who are unable to attend in person.

Key Points: 
  • The event will also be webcasted for those who are unable to attend in person.
  • Patty Keating, patient and Chairwoman of the HypoPARAthyroidism Association, will share her personal experience living with the disease and challenges with the current standard of care.
  • Mark Sumeray, M.D., chief medical officer of Amolyt Pharma, will provide an update on the Calypso study, a Phase 3 clinical trial of eneboparatide for the treatment of patients with hypoparathyroidism.
  • A live question and answer session will follow the formal presentations.

Personalis Announces Two Abstracts Accepted for Presentation at ASCO 2023

Retrieved on: 
Tuesday, May 30, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, ICIS, University, ICI, PPM, Duke Cancer Institute, Neoplasm, Survival, American Society of Clinical Oncology, RECIST, Cancer, Hope, University of North Carolina at Charlotte shooting, LOD, PSNL, ASCO, MRD, NeXT, MD, Patient, McMaster University Medical Centre, Melanoma, Kinetics, Stomach, Society, Medical imaging, Chief Justice of Hungary

Personalis, Inc. (Nasdaq: PSNL) today announced it will present new clinical data as scientific posters at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023, which convenes from June 2-6, 2023, in Chicago, Ill.

Key Points: 
  • Personalis, Inc. (Nasdaq: PSNL) today announced it will present new clinical data as scientific posters at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023, which convenes from June 2-6, 2023, in Chicago, Ill.
  • “Monitoring patient response to ICI therapy using current technologies is often limited in scope and resolution,” explains Christopher Hall, Chief Executive Officer and President at Personalis.
  • At ASCO, Personalis will present data from two retrospective clinical studies that demonstrate a breakthrough in ctDNA detection sensitivity.
  • Details of the Personalis abstracts are outlined below, and further details about the poster presentations can be found here .

Akston Biosciences Doses First Volunteers in Phase II/III Clinical Trial of Low Cost, Shelf Stable COVID-19 Vaccine

Retrieved on: 
Thursday, April 7, 2022
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Merck & Co., Population, Therapy, WHO, Vaccination, Interim, Partnership, ANVISA, Clinical trial, Multimedia, Fahrenheit, Coronavirus, Martek Biosciences Corporation, UK, Phase, Vaccine, EUA, Research, Delta, Merck, CEO, Developing country, Autoimmune disease, Immunoglobulin G, McMaster University Medical Centre, Omicron, USFDA, Safety, SmartCell Technology, RNA transfection, Emergency Use Authorization, CDSCO, COVID-19, Porantha Veeda Puguntha Veeda, COVID-19 vaccine, RBD, GMP, Patient, Shrikant Deshpande, Volunteering, Infection, Pharmaceutical industry

Akston Biosciences Corporation , a developer of new classes of biologic therapeutics, announced today that the first volunteers in a Phase II/III clinical study of AKS-452, its low cost, shelf stable protein subunit COVID-19 vaccine, were dosed in India.

Key Points: 
  • Akston Biosciences Corporation , a developer of new classes of biologic therapeutics, announced today that the first volunteers in a Phase II/III clinical study of AKS-452, its low cost, shelf stable protein subunit COVID-19 vaccine, were dosed in India.
  • View the full release here: https://www.businesswire.com/news/home/20220406006130/en/
    The first volunteer receives Akston Biosciences COVID-19 vaccine, AKS-452, as part of a Phase II/III double-blind placebo-controlled study in India.
  • (Photo: Business Wire)
    The multicenter trial will complete the enrollment of 1,500 healthy volunteers, age 18 and older, who will receive two 90 g doses 28 days apart.
  • This clinical trial represents an important step in the development of protein-based COVID-19 vaccines, said Todd Zion, Ph.D., President & CEO of Akston Biosciences.

Stream 'Let Kids Be Kids': An Unfiltered Medical Discussion on How COVID-19 Restrictions Impact Children

Retrieved on: 
Monday, January 24, 2022
Family medicine, Research, LinkedIn, McMaster University Medical Centre, COVID-19, School, Solution, Government, Department, McMaster, Android, Medical practice management software, Instagram, Q&A, Psychiatry, Continuing medical education, Parent, YouTube, Associate, Associate professor, Family, Bronowski Institute of Behavioural Neuroscience, Virtual event, McMaster University, Kids for Kids, Twitter, Friends, IOS, Partnership, Social media, Bandy, Vaccine, Pharmaceutical industry, Public relations, Facebook

There has also been much debate about vaccinating children.

Key Points: 
  • There has also been much debate about vaccinating children.
  • On Wednesday, January 19, video conferencing solution and virtual events producer, Banty Inc. , gathered a panel of medical experts for an unfiltered discussion focused on how government-led COVID-19 restrictions have impacted the lives of children.
  • Due to popular demand, a 90-minute recording of the Let Kids Be Kids event is now available online.
  • Her lengthy, impassioned and research-driven presentation resulted in high-praise from attendees, as well as an engaging Q&A session with them.

Banty Presents Successful COVID-19 Educational Event 'Let Kids Be Kids'

Retrieved on: 
Friday, January 21, 2022
Family medicine, LinkedIn, McMaster University Medical Centre, COVID-19, Solution, Government, Department, Android, Medical practice consultants, Instagram, Q&A, School, Psychiatry, YouTube, Associate, Associate professor, Family, Bronowski Institute of Behavioural Neuroscience, Virtual event, McMaster University, Kids for Kids, Twitter, IOS, Social media, Bandy, Nightclub, Pharmaceutical industry, Facebook

TORONTO, Jan. 21, 2022 /PRNewswire/ --On Wednesday, January 19, video conferencing solution and virtual live event producer, Banty Inc. , presented Let Kids Be Kids, an online educational gathering focused on COVID-19's impact on children.

Key Points: 
  • TORONTO, Jan. 21, 2022 /PRNewswire/ --On Wednesday, January 19, video conferencing solution and virtual live event producer, Banty Inc. , presented Let Kids Be Kids, an online educational gathering focused on COVID-19's impact on children.
  • In the near-term, Banty will make footage from the Let Kids Be Kids event available online.
  • "I could not be happier with how Let Kids Be Kids turned out," offers Dr. Tytus.
  • He continues: "Banty made it possible for Let Kids Be Kids to put forward a high-quality virtual event in a space that was both engaging and interactive.

Maastricht Univerisity Medical Center Commences Procedures

Retrieved on: 
Wednesday, February 24, 2021
Medical devices, Health, Hospitals, Radiology, Cardiology, Biotechnology, Catheter ablation, McMaster University Medical Centre, Magnetic resonance imaging, Elective, Medicine, ONTARIO, Health care

Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in MRI-guided cardiac ablation products, is pleased to announce the Maastricht University Medical Centre+ (MUMC+) in the Netherlands has commenced procedures since the extended lockdowns across Europe precluded elective surgeries.

Key Points: 
  • Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in MRI-guided cardiac ablation products, is pleased to announce the Maastricht University Medical Centre+ (MUMC+) in the Netherlands has commenced procedures since the extended lockdowns across Europe precluded elective surgeries.
  • While we have just started in iCMR, it is obvious to see the future of this technology and where it will take us and patient treatment.
  • Imricors Chair and CEO, Steve Wedan, commented: This is great news and an exciting step forward, as we start to put COVID behind us.
  • We continue to actively plan for the easing of COVID restrictions, including scheduling training and installation at new sites and supporting the recommencement of procedures at existing sites.